AIMS/HYPOTHESIS: The Finnish diabetes risk questionnaire is a widely used, simple tool for identification of those at risk for drug-treated type 2 diabetes. We updated the risk questionnaire by using clinically diagnosed and screen-detected type 2 diabetes instead of drug-treated diabetes as an endpoint and by considering additional predictors. METHODS: Data from 18,301 participants in studies of the Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) project with baseline and follow-up information on oral glucose tolerance status were included. Incidence of type 2 diabetes within 5 years was used as the outcome variable. Improvement in discrimination and classification of the logistic regression model was assessed by the area under the receiver-operating characteristic (ROC) curve and by the net reclassification improvement. Internal validation was by bootstrapping techniques. RESULTS: Of the 18,301 participants, 844 developed type 2 diabetes in a period of 5 years (4.6%). The Finnish risk score had an area under the ROC curve of 0.742 (95% CI 0.726-0.758). Re-estimation of the regression coefficients improved the area under the ROC curve to 0.766 (95% CI 0.750-0.783). Additional items such as male sex, smoking and family history of diabetes (parent, sibling or both) improved the area under the ROC curve and net reclassification. Bootstrapping showed good internal validity. CONCLUSIONS/ INTERPRETATION: The predictive value of the original Finnish risk questionnaire could be improved by adding information on sex, smoking and family history of diabetes. The DETECT-2 update of the Finnish diabetes risk questionnaire is an adequate and robust predictor for future screen-detected and clinically diagnosed type 2 diabetes in Europid populations.
AIMS/HYPOTHESIS: The Finnish diabetes risk questionnaire is a widely used, simple tool for identification of those at risk for drug-treated type 2 diabetes. We updated the risk questionnaire by using clinically diagnosed and screen-detected type 2 diabetes instead of drug-treated diabetes as an endpoint and by considering additional predictors. METHODS: Data from 18,301 participants in studies of the Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) project with baseline and follow-up information on oral glucose tolerance status were included. Incidence of type 2 diabetes within 5 years was used as the outcome variable. Improvement in discrimination and classification of the logistic regression model was assessed by the area under the receiver-operating characteristic (ROC) curve and by the net reclassification improvement. Internal validation was by bootstrapping techniques. RESULTS: Of the 18,301 participants, 844 developed type 2 diabetes in a period of 5 years (4.6%). The Finnish risk score had an area under the ROC curve of 0.742 (95% CI 0.726-0.758). Re-estimation of the regression coefficients improved the area under the ROC curve to 0.766 (95% CI 0.750-0.783). Additional items such as male sex, smoking and family history of diabetes (parent, sibling or both) improved the area under the ROC curve and net reclassification. Bootstrapping showed good internal validity. CONCLUSIONS/ INTERPRETATION: The predictive value of the original Finnish risk questionnaire could be improved by adding information on sex, smoking and family history of diabetes. The DETECT-2 update of the Finnish diabetes risk questionnaire is an adequate and robust predictor for future screen-detected and clinically diagnosed type 2 diabetes in Europid populations.
Authors: Ewout W Steyerberg; Gerard J J M Borsboom; Hans C van Houwelingen; Marinus J C Eijkemans; J Dik F Habbema Journal: Stat Med Date: 2004-08-30 Impact factor: 2.373
Authors: Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto Journal: Lancet Date: 2006-11-11 Impact factor: 79.321
Authors: A Sandbaek; S J Griffin; G Rutten; M Davies; R Stolk; K Khunti; K Borch-Johnsen; N J Wareham; T Lauritzen Journal: Diabetologia Date: 2008-04-29 Impact factor: 10.122
Authors: M Alssema; D Vistisen; M W Heymans; G Nijpels; C Glümer; P Z Zimmet; J E Shaw; M Eliasson; C D A Stehouwer; A G Tabák; S Colagiuri; K Borch-Johnsen; J M Dekker Journal: Diabetologia Date: 2011-06-10 Impact factor: 10.122
Authors: Antonio Martinez-Millana; Jose-Luis Bayo-Monton; María Argente-Pla; Carlos Fernandez-Llatas; Juan Francisco Merino-Torres; Vicente Traver-Salcedo Journal: Sensors (Basel) Date: 2017-12-29 Impact factor: 3.576
Authors: Richard F Hamman; Edward Horton; Elizabeth Barrett-Connor; George A Bray; Costas A Christophi; Jill Crandall; Jose C Florez; Sarah Fowler; Ronald Goldberg; Steven E Kahn; William C Knowler; John M Lachin; Mary Beth Murphy; Elizabeth Venditti Journal: Diabetes Date: 2014-10-02 Impact factor: 9.461
Authors: Y Heianza; Y Arase; S D Hsieh; K Saito; H Tsuji; S Kodama; S Tanaka; Y Ohashi; H Shimano; N Yamada; S Hara; H Sone Journal: Diabetologia Date: 2012-09-07 Impact factor: 10.122
Authors: Robert Wagner; Barbara Thorand; Martin A Osterhoff; Gabriele Müller; Anja Böhm; Christa Meisinger; Bernd Kowall; Wolfgang Rathmann; Florian Kronenberg; Harald Staiger; Norbert Stefan; Michael Roden; Peter E Schwarz; Andreas F Pfeiffer; Hans-Ulrich Häring; Andreas Fritsche Journal: Diabetologia Date: 2013-08-24 Impact factor: 10.122
Authors: Ali Abbasi; Linda M Peelen; Eva Corpeleijn; Yvonne T van der Schouw; Ronald P Stolk; Annemieke M W Spijkerman; Daphne L van der A; Karel G M Moons; Gerjan Navis; Stephan J L Bakker; Joline W J Beulens Journal: BMJ Date: 2012-09-18